Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
J Scott Sawyer, Bryan D Anderson, Douglas W Beight, Robert M Campbell, Michael L Jones, David K Herron, John W Lampe, Jefferson R McCowan, William T McMillen, Nicholas Mort, Stephen Parsons, Edward C R Smith, Michal Vieth, Leonard C Weir, Lei Yan, Faming Zhang, Jonathan M Yingling
Index: J. Med. Chem. 46 , 3953-3956, (2003)
Full Text: HTML
Abstract
Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TbetaR-I receptor kinase domain.
Related Compounds
Related Articles:
2006-03-23
[J. Med. Chem. 49 , 2138-2142, (2006)]
2003-12-15
[Bioorg. Med. Chem. Lett. 13 , 4355-4359, (2003)]
2006-11-10
[J. Biol. Chem. 281 , 33971-33981, (2006)]
A TGF-β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy.
2014-06-01
[Exp. Eye Res. 123 , 72-86, (2014)]
2016-01-01
[Sci. Rep. 6 , 29479, (2016)]